This website is best viewed using the horizontal display on your tablet device.
An oral small molecule psoriasis therapy selectively inhibiting TYK21*
Adapted from Product Monograph.
- SOTYKTU is a small molecule of that selectively inhibits the TYK2 enzyme
- TYK2 mediates signaling within the IL-23/Th17 pathophysiology pathway of psoriasis including
signaling of IL-23, IL-12, and Type 1 IFN cytokines - SOTYKTU binds to the regulatory domain of TYK2, stabilizing an inhibitory interaction between the regulatory
and the catalytic domains of the enzyme - This results in allosteric inhibition of receptor-mediated activation of TYK2 and its downstream functions in cells
- SOTYKTU inhibits the release of proinflammatory cytokines and chemokines